Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Squalamine Lactate · MSI-1256F

Small molecule · developed by Ohr Pharmaceutical

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Squalamine Lactate?

Squalamine Lactate Ophthalmic Solution is a small-molecule eye drop formulation studied in retinal vein occlusion with macular edema.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MSI-1256F
Drug type
Small molecule
Therapy area
Ophthalmology
Developer
Ohr Pharmaceutical Inc.
In trials of
CPIX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
4WE915J1KX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02614937 Phase 1/2 Retinal Vein Occlusion Completed CPIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Macular EdemaRetinal Vein Occlusion

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.